Latest News

Shape the Future of Hematology by Joining ASH Trainee Council

Deadline to apply is March 30

Details >

FDA Approves Daiichi Sanyko & AstraZenca's Datroway ® (Datopotamab Deruxtecan-dlnk) for the Treatment of Adult Patients With HR Positive, HER2 Negative Breast Cancer

Details >

FDA Approves Amgen's LUMAKRAS® (Sotorasib) in Combination With Vectibix® (Panitumumab) for the Treatment of Adult Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer

Details >

FDA Approves AstraZeneca’s Calquence (Acalabrutinib) in Combination With Bendamustine and Rituximab for Adult Patients With Previously Untreated Mantle Cell Lymphoma

Details >

FDA Approves BeiGene's TEVIMBRA® (tislelizumab-jsgr) First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

Details >

Advocacy

MSHO continuously contacts legislators, provides comments to policy makers, and collaborates with payers on issues of concern to those delivering care to cancer patients.

more information

Education

It is important that our members are aware of meetings, webinars, and other educational opportunities specifically designed to address the complexities of cancer care.

more information

Research

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

more information

MSHO Foundation

The MSHO Foundation is a 501c3 organization which was formed in 2011 to address the growing educational needs of hematology and oncology professionals in Michigan.

more information

Job Board

MSHO offers our members an opportunity to share current job openings or post your resume as a job seeker on our website. Click here to view job openings, posted resumes, or to create a new post.

more information

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
Report Broken Link

Welcome

Latest News

Shape the Future of Hematology by Joining ASH Trainee Council

Deadline to apply is March 30

FDA Approves Daiichi Sanyko & AstraZenca's Datroway ® (Datopotamab Deruxtecan-dlnk) for the Treatment of Adult Patients With HR Positive, HER2 Negative Breast Cancer

FDA Approves Amgen's LUMAKRAS® (Sotorasib) in Combination With Vectibix® (Panitumumab) for the Treatment of Adult Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer

FDA Approves AstraZeneca’s Calquence (Acalabrutinib) in Combination With Bendamustine and Rituximab for Adult Patients With Previously Untreated Mantle Cell Lymphoma

FDA Approves BeiGene's TEVIMBRA® (tislelizumab-jsgr) First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

Advocacy

Education

Research

MSHO Foundation

Job Board

Report Broken Links